L ife-threatening heart diseases, such as myocardial infarction and heart failure, are major causes of death in developed countries. Because of the almost nonexistent cardiomyocyte turnover in the human heart after birth, recovery of cardiac function after heart disease is insufficient. 1-3 The low levels of proliferation and regeneration ability of cardiomyocytes must be overcome to treat these diseases effectively. Although numerous causes of postnatal cell-cycle arrest were extensively investigated, such as balances of cyclins, cyclindependent kinases, cyclin-dependent kinase inhibitors, 4 growth factors, 5-9 transcription factors, 10-14 and microRNA, 15 heart regenerative medicine has not been effective. One of the limitations is lack of efficient methods for manipulating multiple factors simultaneously.
We hypothesized that a chemical biological approach would be a suitable answer to this problem. Compared with conventional genetic methods, chemical biological approaches for exploring key biological mechanisms have many advantages, enabling temporal control, rapid inhibition or activation, and regulation of functionally overlapping targets. 16, 17 Moreover, chemicals can function across similar species and can be applied directly as therapeutic drugs. Thus, identifying novel chemicals would be an efficient approach to elucidate novel mechanisms regulating cardiomyocyte proliferation and finally use cardiac regeneration as a therapeutic strategy. Nevertheless, no efficient chemical screening platform for cardiomyocyte proliferation has been explored to date. Recent advances in imaging and analyzing have led to novel approaches to analyze numerous samples automatically. These cell-and imaging-based methods to screen are called high-content screening (HCS), providing various information on cellular phenotype, including cell division. 18 Pluripotent stem cells (PSCs), including both embryonic stem cells (ESCs) and induced PSCs (iPSCs), have great potentials for therapeutic purpose and for drug discovery as they can give rise to any cell types, including cardiomyocytes. [19] [20] [21] [22] [23] We have been investigating cardiovascular cell differentiation and regeneration with the use of PSCs and have established efficient methods for cardiac differentiation from mouse and human PSCs. [24] [25] [26] [27] [28] Here, we combined our stem cell technology and chemical biology with HCS to identify chemicals inducing cardiomyocyte proliferation. We successfully identified several chemicals with distinct molecular targets and confirmed their proliferative effects on cardiomyocytes from mouse PSCs. We further demonstrated the chemical-induced effects on cardiomyocytes from different stages of maturation: embryos, neonates, and adults. This study provides novel understanding for molecular machineries and would offer efficient ways to regulate cardiomyocyte proliferation with chemicals.
Methods

Reagents and Antibodies
The SCADS inhibitor kit containing ≈280 well-established kinase inhibitors 29, 30 was a gift from the Screening Committee of Anticancer Drugs supported by a Grant-in-Aid for Scientific Research on Priority Area "Cancer" from The Ministry of Education, Culture, Sports, Science and Technology, Japan. See Methods in the online-only Data Supplement for reagents and antibodies.
High-Content Screening
The screening process is summarized in Figures I and II in the onlineonly Data Supplement. FACS-purified mouse ESC-derived cardiomyocytes (mESCMs) were plated on 0.1% gelatin-coated 96-well plates at 500 cells per well. Cells were treated with chemicals from SCADS inhibitor kit (0.2-5 μmol/L) for 5 days, followed by fixation and staining with anti-α-myosin heavy chain (αMHC) antibody and 4',6-diamidino-2-phenylindole. A 4',6-diamidino-2-phenylindole positive spot in an αMHC-positive area was counted as 1 nucleus ( Figure IIc in the onlineonly Data Supplement). αMHC-positive nuclei in 4 low-magnification fields, covering ≈60% of a single well of 96-well plates, were counted using HCS system ImageXpress (Molecular Devices, Sunnyvale, CA) and image processing software MetaXpress (Molecular Devices).
Statistics
All experiments were repeated ≥3×, except the first screen that was repeated twice. Values were reported as mean±SD and were analyzed by Mann-Whitney test (for 2-group comparison), or by Dunn test (for multiple comparison) using a statistics software, GraphPad Prism (GraphPad Software, Inc, CA). Values of P<0.05 were considered to be statistically significant.
See Methods in the online-only Data Supplement for mouse ESC and human ESC/iPSC culture and differentiation, cardiomyocyte isolation, immunostaining, cell-cycle analysis by flow cytometry, Western blotting, gene knockdown, electrophysiological study, and quantitative reverse transcriptional polymerase chain reaction.
Results
Chemical Library Screening for Cardiomyocyte Proliferation in mESCMs
A mouse ESC line carrying αMHC promoter-driven enhanced green fluorescent protein (αMHC-EGFP) 25 was used to prepare purified early differentiated cardiomyocytes ( Figure I in the online-only Data Supplement), with which we evaluated the chemical-induced effects on cardiomyocyte proliferation. mESCMs appear at 3 to 4 days after Flk1-positive mesoderm cells were cultured on OP9 stroma cells as we previously reported (Flkd3 to d4; Figure I in the online-only Data Supplement). 25, 27 Within a few days after the cells differentiated to cardiomyocytes, they ceased their proliferation similar to cardiomyocytes in vivo. To screen chemicals that exhibit a direct proproliferative effect on mESCMs, we sorted, purified, and recultured αMHC-EGFP-positive mESCMs at Flkd6 (Figure IIb-IId in the online-only Data Supplement). For the primary screen, we performed HCS to count directly the number of cardiomyocyte nuclei ( Figure IIc in the online-only Data Supplement). Purified mESCMs were replated on 96-well plate with treatment of each chemical from the SCADS inhibitor kit in 3 concentrations (0.2, 1, and 5 μmol/L). Five days after treatment (Flkd6+5), the average number of mESCM nuclei was 35.6±17.5 (cells per field, n=35) in the control condition. Seven chemicals increased mESCM nucleus number more than mean+2 SD of control (red spots in Figure 1A ; Table I in the online-only Data Supplement). Two Ca 2+ /calmodulindependent protein kinase II (CaMKII) inhibitors increased the number of mESCM nuclei more than mean+1 SD of control (blue spots in Figure 1A ; Table I in the online-only Data Supplement).
Because >80% of murine mature cardiomyocytes in adults are reported to have 2 nuclei, 1, 31 an increase in the number of cardiomyocyte nuclei may not directly reflect the actual increase in the number of cardiomyocytes. To evaluate the effects of the chemicals on the actual cardiomyocyte number, we performed a secondary screen with 7 small molecules of independent kinase targets among the 9 candidate chemicals ( Table I in the online-only Data Supplement). We purified mESCMs, recultured with chemicals for 5 days, and calculated the actual cardiomyocyte number by cell counting and flow cytometry for αMHC-EGFP ( Figure IId Next, we compared mESCM number between Flkd6+2 and Flkd6+5 to confirm whether these chemicals could actually December 2013 increase cardiomyocyte proliferation and whether they did not simply improve the replating viability of mESCMs. Whereas replated mESCMs showed no increase in cell number with dimethyl sulfoxide (DMSO) alone, all 3 chemicals significantly increased mESCM number during Flkd6+2 to Flkd6+5 ( Figure 1C ). We further confirmed cardiomyocyte proliferation with time-lapse video recording ( Figure 1D ; Movies I-IV in the online-only Data Supplement). Whereas a control cardiomyocyte (Movie I in the online-only Data Supplement) ceased proliferation and just underwent hypertrophic change, cardiomyocytes treated with these chemicals caused cell division and proliferation (Movies II-IV in the online-only Data Supplement). These data clearly show that the 3 chemicals (BIO, SU1498, and KN93) enhance mESCM proliferation and increase in mESCM number accompanying actual cell division but not binucleation.
Induction of Cell-Cycle Progression in Cardiomyocytes by Chemicals
Next, we examined changes in mESCM cell cycle. The ratio of S phase in mESCMs, as estimated with 3-hour pulse-labeled 5-ethynyl-2´-deoxyuridine (EdU) incorporation, and the ratio of M phase in mESCMs, as estimated by immunostaining of phosphorylated histone H3 (pH3) at Flkd6+3, were increased >2.2× by BIO treatment and increased ≈1.5 to 2× by SU1498 and KN93 (Figure 2A -2C). The ratio of 4N cardiomyocytes was examined as doubled DNA contents (4N) and EdU-negative cells in cardiac troponin T-positive population by flow cytometry. 4N cardiomyocytes, consisting of cells in G2/M phase and cells with binuclei, were not increased by any chemical treatment but reduced by KN93 treatment compared with DMSO treatment, suggesting that binuclear cardiomyocytes were not induced by these chemicals ( Figure 2D ). Western blotting for cyclins showed that BIO, but not SU1498 or KN93, treatment increased cyclin D2 and cyclin D3 ( Figure 2E ) as reported. 32 In addition to the increase of cyclin Ds, a cyclin-dependent kinase inhibitor, Ink4b expression was downregulated 30% by treatment of each chemical at Flkd6+2 ( Figure 2F ). Downregulation of Ink4b was sustained until Flkd6+5 in SU1498 or KN93 treatment ( Figure 2G ). These results indicate that these chemicals actually induce cell-cycle progression in cardiomyocytes by regulating cyclin/ cyclin-dependent kinase activity.
Molecular Targets of the Chemicals
Next we confirmed the molecular targets of these 3 chemicals. Addition of CHIR99021, another GSK3-specific inhibitor ( Figure 3A ), or Wnt3a (data not shown) increased cardiomyocyte numbers similar to BIO, indicating that inhibition of GSK3 enhanced mESCM proliferation as reported in rat cardiomyocytes. 32 Figure 1 . Three chemicals were identified with chemical library screening for mouse embryonic stem cell-derived cardiomyocyte (mESCM) proliferation. A, Primary screen with high-content screening for nucleus numbers in α-myosin heavy chain (αMHC)-positive cells (mESCMs). Mean nucleus numbers at Flkd6+5 treated with ≈280 chemicals at 3 concentrations (• 5 μmol/L, ◼ 1 μmol/L, and ▲ 0.2 μmol/L; n=2). Seven chemicals (red symbols) increased mESCMs more than mean+2 SD of control (control: n=35). Two Ca 2+ /calmodulin-dependent protein kinase II inhibitors (blue symbols) increased mESCM more than mean+1 SD. B, Secondary screen for the 7 chemicals calculating actual cardiomyocyte numbers with flow cytometry. Concentration: AGT 5 μmol/L, BIO 1 μmol/L, NU6102 5 μmol/L, HA14-1 1 μmol/L, SU1498 5 μmol/L, Gli 5 μmol/L, and KN93 5 μmol/L. *P<0.05, **P<0.01 vs dimethyl sulfoxide (DMSO) treatment (Dunn test for multiple comparisons, n=3-11). C, Chemicals increased mESCM numbers during Flkd6+2 to Flkd6+5. P value: Mann-Whitney test, n=3. D, Captured images from time-lapse video recording during Flkd6+0.5 (0:00) to 4.5 (96:00). AGT indicates aminoglutethimide; GFP, green fluorescent protein; and Gli, glibenclamide.
SU1498, first reported as a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 (also designated as Flk1), 33 enhanced cardiomyocyte proliferation, although Flk1 is not expressed in mESCMs, 25 suggesting that SU1498 exerted its effect through targets other than Flk1. SU1498 was reported to cause accumulation of phosphorylated extracellular signal-regulated kinase (ERK) via inhibiting phosphatase binding to ERK. 34 We performed Western blot analysis to show whether SU1498 causes accumulation of phosphorylated ERK in mESCMs. Phosphorylation of ERK was increased only when cells were treated by SU1498 but not with BIO or KN93 ( Figure 3B ). Then we determined whether SU1498elicited mESCM proliferation is mediated by ERK signaling. Treatment with a mitogen-activated protein kinase (MAPK)/ ERK kinase (MEK) inhibitor PD98059 (PD) that inhibits ERK phosphorylation abolished the increase in SU1498-induced mESCMs ( Figure 3C ). In addition, ZM336372 (ZM), an activator of Raf1/ERK signaling, similarly increased mESCM number ( Figure 3C ). Furthermore, an ERK activating growth factor, neuregulin-1 beta, also increased mESCM numbers by ≈1.5× (data not shown) as reported. 9, 35 Taken together, these data indicate that SU1498 increases cardiomyocyte proliferation through activation of Raf-MEK-ERK signal cascade. 7, 36 CaMKII was reported to be involved in cardiomyocyte hypertrophy, but little is known about its role in cardiomyocyte proliferation. Two distinct CaMKII inhibitors, KN93 and KN62, similarly increased cardiomyocyte numbers ( Figure  3D ), suggesting that CaMKII is a novel regulator of cardiomyocyte proliferation. We investigated the role of CaMKII in cardiomyocyte proliferation. CaMKII is a family protein coded by the Camk2a, Camk2b, Camk2d, and Camk2g isoform genes. Among them, Camk2a, Camk2d, and Camk2g mRNA, but not Camk2b mRNA, expressions were detected in purified mESCM at Flkd6 (data not shown). We evaluated the effect of specific small interfering RNA against each CaMKII isoform to identify the main isoform(s) that inhibit mESCM proliferation. Specific knockdown of Camk2d and 2g, the major CaMKII isoforms in cardiomyocytes, 37 by small interfering RNA increased mESCM cell numbers by 50% ( Figure  IIIa Our results, thus, show that these chemicals affect cardiomyocyte proliferation through distinct pathways-BIO/GSK3, SU1498/ERK, and KNs/CaMKII.
Combinatory Effects of Chemicals on mESCM Proliferation
Distinct molecular targets of these chemicals prompted us to examine combinations of inhibitors to maximize their proliferative effects. We first examined combinations of 2 inhibitors. BIO+SU1498 (SU) and BIO+KN93 (KN) significantly increased mESCM proliferation ( Figure 4A ). Unexpectedly, In addition, a combination of all 3 inhibitors, BIO+SU+KN, showed no effect on cardiomyocyte proliferation ( Figure  4A ), suggesting that SU1498 and KN93 could be conflicting in the cardiomyocyte proliferation machinery. A p38 MAPK inhibitor SB203580 (p38i) is known to increase neonatal or adult cardiomyocyte proliferation. 38 In fact, p38i (1 μmol/L) significantly increased the mESCM number by ≈2-fold also in our experimental system ( Figure 4B ). Therefore, we added p38i to each combination and found that BIO+SU+p38i and BIO+KN+p38i increased in mESCM numbers ≈ 6 to 7 times more than control until the mESCMs reached confluency (data not shown). To allow more robust proliferation, we next tested mESCM culture at a lower cell density (5.0×10 4 /well [6-well plate]). In this condition, the BIO+SU+p38i combination increased mESCM ≈14-fold ( Figure 4C ). We also examined cell cycle of mESCMs treated with each combination ( Figure  4D ). Both combinations (BIO+SU+p38i and BIO+KN+p38i) significantly increased EdU (3-hour pulse) incorporation to ≈2.5 and 4 times more than DMSO treatment at Flkd6+3 and Flkd6+5, respectively ( Figure 4D ). These combinations also significantly increased pH3 in mESCMs up to ≈2.7 and 2.5 times more than DMSO treatment at Flkd6+3 and Flkd6+5, respectively ( Figure 4D ). We also evaluated 4N fraction (G2/M and binucleated cardiomyocytes) by flow cytometry, but there were no significant differences (data not shown). Thus, we successfully demonstrated that optimal combinations of the chemicals effectively induced substantial cardiomyocyte proliferation. We collectively named these 7 chemicals (BIO, CHIR99021, SU1498, ZM336372, KN93, KN62, and p38i) cardiomyocyte proliferative chemicals (CPCs).
We further confirmed cardiomyocyte features after proliferation. All αMHC-EGFP-positive cells used in our study were also positive for cardiac troponin T ( Figure I in the online-only Data Supplement). These cells were spontaneously beating before and after the chemical treatments. Proliferated cardiomyocytes with combined CPC treatments (BIO+SU1498+p38i and BIO+KN93+p38i) showed similar cardiomyocyte-like action potentials ( Figure IVa Supplement). The data demonstrated that CPCs enhanced proliferation of cardiomyocytes with no apparent bias in cardiomyocyte features.
Developmental Stage-Specific Effects of Chemicals on Embryonic, Neonatal, and Adult Cardiomyocytes
Next, we examined the effects of CPCs on cardiomyocytes in various developmental stages, such as embryos, neonates, and adults. Cardiomyocytes isolated from the hearts of E9.5 mice, which is in comparable differentiation stage with mESCMs, 39 were cultured and treated with each CPC or with the combinations for 3 to 5 days (E9.5+3 and E9.5+5, respectively). Each CPC treatment increased the S and M phases in embryonic cardiomyocytes at E9.5+3 ( Figure Va in the online-only Data Supplement). Combined CPC treatments (BIO+p38i+SU/ KN) increased S phase to ≈4.5× and M phase to 3 times more than control at E9.5+3 ( Figure Va in the online-only Data Supplement). Combined CPC treatments rapidly increased embryonic cardiomyocyte nuclei number ≈ 8.5 times more than control at E9.5+5 ( Figure V in the online-only Data Supplement). These data indicated that CPCs efficiently proliferate embryonic cardiomyocytes in a similar manner to those in mESCMs.
Neonatal (P3) rat ventricular cardiomyocytes were isolated and cultured with CPCs for 2 days. As a baseline, DMSO-treated neonatal cardiomyocytes rarely proliferated (5-bromo-2'-deoxyuridine [BrdU]-positive cells, 3.4±0.3%; pH3-positive cells, 0.37±0.08%; Aurora B-positive cells, 0.36±0.04%). BIO, SU1498, or p38i alone increased in number of BrdU-positive cardiomyocytes by 2 to 3.5 times ( Figure 5A) . In contrast to mESCMs and embryonic cardiomyocytes, KN93 failed to increase BrdU incorporation and further progression of the cell cycle in neonatal (P3) rat ventricular cardiomyocytes (BrdU-positive cells, 4.1±1.4%; Figure 5A ). Combination of BIO+p38i synergistically increased BrdU incorporation and BIO+SU+p38i further enhanced the BrdU incorporation (19.4±2.2% and 25.0±2.6%, respectively; P<0.05 versus control; Figure 5A ). In BIO+p38i and BIO+p38i+SU1498 conditions, the cell-cycle progression to M phase (pH3-positive, 3.70±0.20% and 4.03±0.19%, respectively; Figure 5B ) and cell division (Aurora B positive, 3.47±0.21% and 3.76±0.24%, respectively; Figure 5C ) were significantly increased compared with the baseline.
Adult rat cardiomyocytes were isolated and cultured with CPCs for 6 days. Less than 0.01% of adult cardiomyocytes were positive for BrdU, and none of them was pH3 positive at the baseline (DMSO treatment). BIO or p38i treatment alone evoked cell-cycle re-entry in adult cardiomyocytes, that is, BrdUpositive and pH3-positive cells were increased ( Figure 5D ). Combination of BIO and p38i synergistically and significantly enhanced the cell-cycle progression markers in adult cardiomyocytes compared with baseline (BrdU-positive cells, 2.7±0.3%; pH3-positive cells, 0.60±0.05%; Aurora B-positive cells, 0.37±0.07%; Figure 5D -5G). pH3-positive metaphase and anaphase cardiomyocytes were found in BIO+p38i condition ( Figure 5F ). In contrast, SU1498 and KN93 failed to enhance the effects of BIO+p38i (Figure 5D and 5E) .
These findings suggest that GSK3 and p38 MAPK are broadly and cooperatively regulating various cardiomyocytes including in adults, whereas ERK and CaMKII play a novel developmental stage-specific function.
Effects of Chemicals on Cardiomyocytes from Human iPSCs and ESCs
Finally, we evaluated the effects of CPCs on human iPSC-and ESC-derived cardiomyocytes. A human iPSC line 201B6 is 1 of the most characterized 4-factor (Oct3/4, Sox2, c-myc, and Klf4) iPSCs for differentiation properties, including cardiac differentiation. 28, 40 Cardiomyocytes (human induced pluripotent stem cell derived cardiomyocytes [hiPSCMs]) were induced with a 2-dimensional, defined, serum-free condition-based cardiomyocyte differentiation method ( Figure 6A ). 22, 28 Spontaneously beating hiPSCMs appeared ≈8-10 days after activin A treatment. At day 11, CPC treatment was started. The cell cycle was evaluated by flow cytometry at day 14, and the cardiomyocyte number was calculated at day 16. In agreement with the results from mESCMs, BIO+p38i+SU significantly increased EdU incorporation in hiPSCMs at day 14 ( Figure 6B and 6C) and hiPSCM number at day 16 ( Figure 6D ). BIO+p38i+KN had tendencies to increase EdU incorporation and hiPSCM number ( Figure 6B-6D) . Similarly, BIO+p38i+SU increased BrdU incorporation in hESC-derived cardiomyocytes by ≈1.5× (data not shown). We purified hiPSCMs with a recently identified cell-surface marker for hiPSCMs, VCAM1, 28 and evaluated structural and functional features of CPC-expanded hiPSCMs. CPC-expanded hiPSCMs showed clear sarcomere formation ( Figure 6E ) and action potentials ( Figure 6F ), similar to those in control hiPSCMs. These data indicate that CPCs also successfully work in human cardiomyocytes.
Discussion
In the present study, we screened a chemical library with an HCS for effects on the proliferation of mESCMs and succeeded in identifying several distinct chemicals promoting cardiomyocyte proliferation. These findings uncovered common and developmental stage-specific machineries controlling cardiomyocyte proliferation. They also would provide broad and efficient ways of manipulating cardiomyocyte number from embryos to adults and in mouse and human.
We identified chemicals regulating 4 distinct signaling pathways, namely, GSK3 (BIO and CHIR99021), ERK (SU1498 and ZM336372), CaMKII (KN93 and KN62), and p38 MAPK ). E, Immunostaining for α-actinin at day 16+5 to 7. Scale bar=100 μm. F, Representative action potential of purified VCAM1-positive cells and graphs for action potential parameters at day 16+5. No significant difference vs control (n=17). APD50 indicates action potential duration; bFGF, basic fibroblast growth factor; BMP4, bone morphogenetic protein 4; dV/dt, maximum rate of depolarization; EdU, 5-ethynyl-2´-deoxyuridine; EPS, electrophysiological study; hipSCM,human induced pluripotent stem cell derived cardiomyocytes; I, Immuno staining for α-actinin at day 16+5 to 7; ICC, immunocytochemistry; MDP, mean diastolic potential; qPCR, quantitative reverse transcriptional polymerase chain reaction; and VCAM1, vascular cell adhesion molecule 1.
(SB203580; Figure 7 ). Consistent with previous reports, 32, 38 GSK3 and p38 MAPK signal cascades negatively regulated cardiomyocyte proliferation and inhibitors of these kinases enhanced rodent and human cardiomyocyte proliferation. This is the first report to show synergistic effects of combinatorial inhibition of GSK3 and p38 MAPK, especially on adult cardiomyocyte proliferation.
In contrast to GSK3 and p38 MAPK inhibitors, ERK activators and CaMKII inhibitors have not been reported to be involved in cardiomyocyte proliferation. Raf-MEK-ERK signal cascade positively regulates the proliferation of cardiomyocytes as a downstream target of growth factors. 7, 8 Furthermore, phospho-ERK is evident in E8.0 heart, which depends on the fibroblast growth factor receptor. 41 SU1498 enhances ERK phosphorylation through inhibiting phosphatase ( Figure 3B ). 34 Phosphatases, such as dual-specificity phosphatase 6, negatively regulate ERK phosphorylation. 42 Dual-specificity phosphatase 6 null mice showed enhanced ERK phosphorylation and increased cardiomyocyte proliferation during embryonic development and in the early postnatal period. 36 Dual-specificity phosphatase 6 is a possible candidate for a SU1498 target. A Raf activator, ZM336372, also showed a similar proproliferative effect. Collectively, all of these results indicate that activation of Raf-MEK-ERK pathway could be a potent molecular target to induce cardiomyocyte proliferation. CaMKII has been reported to regulate cardiac hypertrophy in the later stages of development or in adults. 43, 44 Here, we showed that in an earlier developmental stage corresponding to E9.5 mouse embryos, CaMKII could inhibit cardiomyocyte proliferation. We confirmed phosphorylation of CaMKII in early mouse embryos (E9.5 and E13.5) and found that CaMKII phosphorylation was drastically increased between E9.5 and E13.5 ( Figure VI in the online-only Data Supplement). CaMKII phosphorylation was more evident in trabecular layer cardiomyocytes than in compact layer counterparts at E13.5. This timing of CaMKII activation in trabecular cardiomyocytes is in accordance with the period when the proliferative ability of trabecular layer cardiomyocytes is reduced, 13 suggesting that CaMKII at this differentiation stage could be involved in growth arrest of early cardiomyocytes. CaMKII inhibitors lost its proliferative effect on postnatal and adult cardiomyocytes, suggesting that the growth inhibitory effect of CaMKII has an early developmental stage-specific effect, and switching of its effect to hypertrophy would occur in the later stage. Currently, the precise molecular mechanisms for the developmental stage-specific CaMKII effect are unknown, but this finding is a clue to the precise understanding of CaMKII functions in cardiomyocytes.
Although ERK activators and CaMKII inhibitors did not show sufficient proliferative effects in adult cardiomyocytes, our finding of an effective chemical cocktail for cardiomyocyte proliferation can offer a therapeutic potential for cardiac regeneration. In diseased hearts, cardiomyocytes express embryonic genes, 45 and a small fraction of cardiomyocytes is dedifferentiated and proliferating 3 or newly differentiated from progenitor cells, 46 indicating that these cardiomyocytes in diseased hearts are in a more immature stage. Hence, the combination of GSK inhibitors and p38i as well as our effective cocktails, including 3 chemicals, exerts their potent proproliferative effects in diseased hearts, facilitating cardiac regeneration. Figure 7 . Scheme of regulatory machinery of cardiomyocyte proliferation. Four distinct signaling pathways, glycogen synthase kinase-3 (GSK3), p38 mitogen-activated protein kinase (MAPK), Ca 2+ / calmodulin-dependent protein kinase II (CaMKII) signaling negatively, and extracellular signal-regulated kinase (ERK) signaling positively, regulate cardiomyocyte proliferation. Inhibitors for GSK3 (BIO and CHIR), p38 MAPK (SB203580), and CaMKII (KN93 and KN62), and activators for ERK (SU1498 and ZM336372) can be used to induce cardiomyocyte proliferation. A combinatory regulation of these signaling efficiently enhances each effect. We named these chemicals as cardiomyocyte-proliferating chemicals (CPCs). CPCs show developmental stage-specific effects. CaMKII inhibitors act only on embryonic and PSC-derived cardiomyocytes. ERK activators still work on neonatal cardiomyocytes but not in adult cardiomyocytes. GSK3 and p38 MAPK inhibitors synergistically enhance cardiomyocyte proliferation broadly even in adults. hipSCM indicates human induced pluripotent stem cell derived cardiomyocytes; and mESC, mouse ESC.
Recently, PSC-derived cells have drawn considerable interest for use in drug screening and disease modeling, 20, 21, 47 and for regenerative medicine, cell therapies 48 are highlighted. In addition, PSC-derived cells can provide an experimental system for studying cellular physiology especially in cell types difficult to obtain from adults. With the use of our PSC systems, it is likely that other more effective chemicals would be identified from other libraries. Thus, our novel screening system for cardiomyocyte proliferation combining stem cell technology and chemical biology could be a potent tool for investigating efficient molecules and largely contributes to future cardiac regenerative medicine, especially through regeneration with drugs.
